MTOR and melanoma: They found that metformin whose mechanism was to inhibit the energy-sensitive LKB1-AMPK/mTOR signaling pathway and then to reduce protein synthesis and cell proliferation did not block BRAF-mutant melanoma cells growth due to the elevated protein kinase RSK activity and the increased VEGF-A protein production.